| apixaban versus placebo | |||
| APPRAISE 2, 2011 NCT00831441 | apixaban 5mg twice daily versus placebo | patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events | double blind Follow-up duration: 8 months 39 countries |
| APPRAISE-1 (10mg od), 2009 NCT00313300 | apixaban 10 mg once daily versus placebo | patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days) | double blind Follow-up duration: 6 months Europe, Middle East, North America |
| APPRAISE-1 (2.5 mg bid), 2009 NCT00313300 | Apixaban 2.5mg twice daily
versus placebo | patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days) | double blind Follow-up duration: 6 months Europe, Middle East, North America |
| rivaroxaban 2.5mg versus placebo | |||
| ATLAS ACS 2 - TIMI 51 (2.5mg), 2011 NCT00809965 | rivaroxaban 2.5 mg twice daily in addition to standard care versus placebo | patients with a recent ACS | double blind Follow-up duration: 13 months 44 countries |
| rivaroxaban 5mg versus placebo | |||
| ATLAS ACS 2 - TIMI 51 (5mg), 2011 NCT00809965 | rivaroxaban 5 mg twice daily in addition to standard care
versus placebo | patients with a recent ACS | double blind Follow-up duration: 13 months 44 countries |
| ximelagatran versus placebo | |||
| ESTEEM, 2003 | oral ximelagatran at doses of
24 mg, 36 mg, 48 mg, or 60 mg twice daily versus placebo | patients who had had recent ST-elevation or non-STelevation myocardial infarction | double-blind Follow-up duration: 6 months |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
